Yu Group: grim reading and very challenging outlook
Full year results for the year to 31 December 2019 from business utility supplier Yü Group PLC (LON; YU.), make for grim reading and the short term outlook is clearly very challenging.
While revenue increased 38% £111.6m, the group still incurred a pre-tax loss of £5.9m, although this was an improvement on the prior year’s £9.6m.
Contracted revenue for 2020 of £79.5m at the period end offers some reassurance, but…
Sign up and read the full article
Register to continue reading our content.
Get FREE access now
Already a member? Login
Previous article
Next article
More on H&T Group
09/01/2025 · Company Insights
A small company covered here supporting the defence sector continues to do nicely, securing another important…
31/08/2024 · Podcasts
In this episode of the Investors Champion Podcast, Chris and Lee delve into key market movers,…
More on Sage Group
11/02/2025 · Portfolio
Our portfolio of high-quality companies offers something for everyone, as you will appreciate in another of…
29/12/2024 · Podcasts
In this episode of the Investor’s Champion Podcast, hosts Chris and Lee discuss the performance of…
More on SigmaRoc
15/09/2024 · Podcasts
In this episode of the Investors Champion Podcast, hosts Lee and Chris focus on news from…
11/09/2024 · Company Insights
There have been plenty of results to digest from many of the smaller AIM companies we follow.…
More on WH Smith
30/01/2025 · Company Insights
News covered here includes our assessment of trading updates from AIM’s online wine retailers. While one…
08/06/2024 · Podcasts
In this episode of the Investors Champion podcast, hosts Chris and Lee discuss the challenges faced…
More on Yu Group
22/01/2025 · Company Insights
News covered here includes our assessment of plenty of trading updates, including another upgrade for a…
28/09/2024 · Podcasts
In this episode of the Investors Champion Podcast, hosts Chris and Lee focus on some outstanding…
More Company Insights
This innovative legal firm continues to deliver
Encouraging news on its AI-driven platform to advance drug development
in neurological disorders
Strong growth, positive outlook and valuation remains modest
More on H&T Group
More on Sage Group
More on SigmaRoc
More on WH Smith
More on Yu Group
More Company Insights